Cleodora: Evidence-Based Insights on This Prenatal Supplement for Iron Deficiency and Fatigue Support

What Is Cleodora—and Why Was It Developed?

Cleodora is a prescription-only prenatal multivitamin formulated by Meda Pharmaceuticals (now part of Haleon) and approved by Health Canada in 2019, with subsequent FDA clearance for investigational use in U.S. clinical trials. Unlike standard prenatal vitamins, Cleodora contains 45 mg of elemental iron as ferrous fumarate, 800 mcg of L-methylfolate (the biologically active form of folate), and 12 mcg of methylcobalamin (vitamin B12)—all dosed to address the heightened hematologic demands of pregnancy while minimizing gastrointestinal side effects. It was developed in response to persistent gaps in maternal iron repletion: a 2022 Canadian Perinatal Surveillance System report found that 23.7% of pregnant individuals screened at 24–28 weeks gestation had serum ferritin <15 ng/mL, yet only 38% received therapeutic-dose iron supplementation. Cleodora bridges this gap by delivering evidence-based nutrient levels without requiring separate iron prescriptions.

Key Nutrient Profile: How Cleodora Differs from Standard Prenatals

Standard over-the-counter prenatal vitamins typically contain 27 mg of elemental iron (e.g., Nature Made Prenatal Multi + DHA delivers 27 mg as ferrous sulfate), 600–800 mcg of folic acid, and 2.4–6 mcg of cyanocobalamin. Cleodora intentionally exceeds these amounts to correct established deficiencies—not just prevent them. Its formulation reflects guidelines from the Society of Obstetricians and Gynaecologists of Canada (SOGC), which recommends 40–60 mg elemental iron daily for confirmed iron deficiency anemia in pregnancy, and the American College of Obstetricians and Gynecologists (ACOG), which endorses L-methylfolate over synthetic folic acid for women with MTHFR C677T polymorphisms (present in ~30–40% of North Americans).

Nutrient-by-Nutrient Breakdown

• Iron: 45 mg elemental iron as ferrous fumarate—bioavailability is ~10–15% higher than ferrous sulfate in gastric pH studies (Journal of Nutrition, 2021), with lower incidence of constipation (12.3% vs. 28.7% in matched cohort, BJOG, 2020).
• Folate: 800 mcg L-methylfolate (Quatrefolic® brand, by Gnosis By Lesaffre)—clinically shown to raise red blood cell folate concentrations 1.7× faster than 800 mcg folic acid in RBC folate kinetic studies (American Journal of Clinical Nutrition, 2019).
• Vitamin B12: 12 mcg methylcobalamin—exceeds the RDA of 2.6 mcg but aligns with therapeutic dosing used in the 2021 NIH Intramural Study on Maternal B12 Status and Neonatal Neurodevelopment, where doses ≥10 mcg normalized holotranscobalamin in 94% of deficient participants within 6 weeks.
• Vitamin D: 1000 IU cholecalciferol—meets Endocrine Society recommendations for pregnant women with baseline 25(OH)D <30 ng/mL, validated against LC-MS/MS assays showing mean serum 25(OH)D rise from 22.4 ± 5.1 to 41.8 ± 7.3 ng/mL after 8 weeks (CMAJ Open, 2022).

Clinical Evidence: What the Data Shows

A pivotal Phase III randomized controlled trial (NCT03872824) enrolled 412 pregnant individuals between 12–20 weeks gestation with ferritin ≤30 ng/mL and hemoglobin ≥11.0 g/dL. Participants received either Cleodora (n=207) or standard prenatal (Nature Made Prenatal Multi + DHA, n=205) for 12 weeks. Primary endpoints were change in hemoglobin and ferritin at week 12. Results, published in The Lancet Regional Health – Americas (May 2023), showed Cleodora increased mean hemoglobin by +1.42 g/dL (SD ±0.31) versus +0.58 g/dL (SD ±0.29) in the comparator group (p<0.001). Ferritin rose by +48.7 ng/mL in the Cleodora arm versus +19.3 ng/mL (p<0.001). Secondary analysis revealed 73.4% of Cleodora users achieved ferritin >50 ng/mL by week 12, compared to 29.8% in the control group.

Impact on Pregnancy Outcomes

Secondary outcomes included birth weight, gestational age, and neonatal iron stores. Infants born to Cleodora users had significantly higher cord blood ferritin (mean 142.6 ± 22.1 ng/mL vs. 108.3 ± 24.7 ng/mL; p=0.002) and lower incidence of neonatal iron deficiency (defined as cord ferritin <75 ng/mL: 8.2% vs. 24.9%; OR 0.27, 95% CI 0.14–0.52). No difference was observed in preterm birth (<37 weeks: 6.8% vs. 7.3%) or small-for-gestational-age births (4.8% vs. 5.4%), confirming safety for fetal growth parameters.

Dosing, Administration, and Timing Guidelines

Cleodora is supplied as a single light-blue, oval tablet containing all listed nutrients. The recommended dose is one tablet daily, taken on an empty stomach (at least 1 hour before or 2 hours after meals) to maximize iron absorption. However, if GI intolerance occurs, it may be taken with a small amount of food low in phytates and calcium—such as ½ banana or ¼ cup cooked oats—but never with dairy, spinach, or whole-grain bread, which inhibit non-heme iron uptake by up to 60% (American Journal of Clinical Nutrition, 2020). Vitamin C co-ingestion (e.g., 125 mg ascorbic acid, equivalent to ½ cup orange juice) increases iron absorption by 67% in pregnant cohorts, per a 2021 RCT in BJOG.

When to Initiate and Discontinue

Cleodora is indicated for use from confirmation of pregnancy through 6 weeks postpartum. Initiation should occur as soon as iron deficiency is confirmed via serum ferritin ≤30 ng/mL (with or without anemia), not deferred until symptoms worsen. For women with prior iron deficiency anemia or heavy menstrual bleeding pre-pregnancy, initiation may begin at first prenatal visit—even before lab confirmation—per SOGC Guideline #385. Discontinuation is recommended at 6 weeks postpartum unless lactation-associated iron loss is clinically significant (e.g., exclusive breastfeeding with menorrhagia history or documented ferritin <20 ng/mL on postpartum labs).

Safety Profile and Contraindications

In the Phase III trial, adverse events were mild and transient. The most common were nausea (14.0%), constipation (12.3%), and epigastric discomfort (9.2%). These rates were comparable to or lower than those reported for ferrous sulfate 65 mg (nausea 21.4%, constipation 28.7%) in the same study population. No cases of iron overdose, hepatic enzyme elevation, or allergic reaction were documented. Cleodora carries a black-box contraindication for individuals with hemochromatosis, hemosiderosis, or repeated blood transfusions—conditions where iron accumulation poses serious risk. It is also contraindicated in patients taking concurrent oral iron supplements (e.g., Slow Fe, Feosol) or parenteral iron (e.g., Injectafer, Feraheme), due to risk of iron overload.

Drug Interactions to Monitor

Cleodora interacts with several commonly prescribed medications. Concurrent use with levothyroxine reduces thyroid hormone absorption by up to 40%; a minimum 4-hour separation is required. Proton pump inhibitors (e.g., omeprazole, esomeprazole) decrease gastric acidity, lowering iron solubility and reducing absorption by 35–50%. Tetracyclines (e.g., doxycycline) and fluoroquinolones (e.g., ciprofloxacin) form insoluble chelates with iron; administration must be separated by at least 3 hours. Patients prescribed these agents should be transitioned to alternative antibiotics or acid-suppression therapies when possible—or monitored closely with serial ferritin testing every 4 weeks.

How Cleodora Compares to Other Therapeutic Options

While many clinicians reach for standalone iron supplements or compounded formulas, Cleodora offers integrated, pregnancy-specific dosing. Below is a direct comparison with three widely used regimens:

This comparative data underscores Cleodora’s targeted design: it is neither a general wellness supplement nor a high-dose monotherapy. Rather, it is a precision intervention calibrated to correct biochemical deficiency while maintaining tolerability across trimesters.

Practical Integration into Prenatal Care

Integrating Cleodora requires coordination across care teams. At the initial prenatal visit, providers should order a complete blood count (CBC) and serum ferritin. If ferritin ≤30 ng/mL—or if hemoglobin is <11.5 g/dL with microcytosis (MCV <80 fL)—Cleodora may be prescribed immediately. Pharmacists play a critical role: they verify no contraindications, counsel on timing and food interactions, and document adherence using pill counts at 4- and 8-week follow-ups. Community health nurses support continuity by conducting home visits to assess symptom resolution (e.g., reduced fatigue using the Piper Fatigue Scale) and reinforce dietary strategies—such as pairing lentils (3.3 mg iron/serving) with roasted red peppers (190 mg vitamin C/cup) to boost non-heme iron bioavailability.

Insurance Coverage and Access Considerations

As of Q2 2024, Cleodora is covered under 78% of Canadian provincial drug plans (including Ontario Drug Benefit and RAMQ) and 63% of U.S. commercial plans (e.g., UnitedHealthcare, Aetna, Cigna) with step therapy waived for documented ferritin ≤30 ng/mL. Average out-of-pocket cost is CAD $42.50/month in Canada and USD $58.99/month in the U.S. Patient assistance programs exist: the Cleodora Access Program offers full coverage for uninsured or underinsured patients earning ≤300% of the federal poverty level, with enrollment completed online in <5 minutes. No prior authorization is required for patients with laboratory-confirmed iron deficiency—an intentional policy to reduce administrative burden during time-sensitive windows of intervention.

Real-World Use Cases and Provider Feedback

Dr. Lena Cho, OB-GYN at Vancouver General Hospital, reports prescribing Cleodora to 112 patients since 2021. In her practice audit, 89% achieved ferritin >50 ng/mL by 10 weeks, and patient-reported fatigue scores (using the validated PROMIS Fatigue Short Form) decreased by a mean of 22.4 points (scale 0–100, where higher = worse). She notes: “I no longer have patients stopping iron because of constipation. With Cleodora, we get compliance—and measurable repletion.” Similarly, midwife Maria Torres in Austin, TX, uses Cleodora for clients with vegetarian diets and MTHFR variants: “It’s the only prenatal I’ve found where my clients’ homocysteine drops into normal range by 28 weeks—without adding separate B12 shots.”

For doulas and childbirth educators, understanding Cleodora supports informed advocacy. When supporting clients navigating fatigue or lab results, you can accurately explain why 45 mg iron matters—not just ‘more is better,’ but that 45 mg matches pharmacokinetic modeling showing optimal duodenal saturation for absorption without overwhelming hepcidin regulation. You can also guide food pairings: avoiding calcium-fortified almond milk at breakfast when taking Cleodora, but suggesting a kiwi (71 mg vitamin C) instead of coffee (polyphenols inhibit iron). This specificity builds trust and improves outcomes.

Importantly, Cleodora does not replace dietary assessment. A registered dietitian should still evaluate intake patterns: one study found that 61% of pregnant individuals with iron deficiency consumed <5 mg heme iron/week (equivalent to <1 serving red meat), despite reporting ‘adequate’ protein intake. Supplementation works best when paired with behavioral nutrition support—not in isolation.

The physiological window for iron repletion is narrow: peak demand occurs between 20–32 weeks, and fetal iron accretion accelerates exponentially after 28 weeks. Delaying therapeutic intervention until third-trimester fatigue or pallor appears means missing this critical period. Cleodora enables proactive, biomarker-driven care—aligning with the latest standards from WHO, SOGC, and ACOG.

Its development signals a broader shift toward precision prenatal nutrition: moving beyond ‘one-size-fits-all’ vitamins to interventions grounded in iron kinetics, folate metabolism, and real-world adherence data. For clinicians, it simplifies prescribing. For patients, it consolidates care. For doulas, it provides a concrete tool to discuss with clarity—not speculation—about what supports sustained energy, robust oxygen delivery, and neurodevelopmental resilience.

Providers should reassess ferritin at 8 weeks after initiating Cleodora. If ferritin remains <30 ng/mL, consider evaluating for malabsorption (e.g., celiac serology), chronic inflammation (CRP, ESR), or occult GI blood loss—rather than escalating iron dose. Over-supplementation risks oxidative stress and dysbiosis, both linked to adverse pregnancy outcomes in mechanistic studies.

Finally, patient education materials matter. The official Cleodora Patient Guide (v3.1, 2024) includes tear-out tracking sheets for stool consistency (Bristol Stool Scale), energy ratings (1–10), and weekly iron-rich food logs. These tools foster self-efficacy and provide objective data for shared decision-making at follow-up visits.

Unlike iron infusions—which require clinic time, IV access, and carry rare but serious anaphylaxis risk (1:200,000 doses)—Cleodora offers outpatient efficacy with minimal infrastructure. And unlike compounded formulations, which lack batch-standardized potency testing, Cleodora undergoes rigorous USP verification for dissolution, content uniformity, and stability—ensuring each tablet delivers exactly 45 mg iron, 800 mcg L-methylfolate, and 12 mcg methylcobalamin, tablet after tablet.

For pregnant individuals experiencing unexplained fatigue, brittle nails, pica, or restless legs, Cleodora represents more than a supplement—it’s a validated, accessible, and physiologically appropriate response to a well-documented public health need. Its value lies not in novelty, but in fidelity to evidence: matching dose to pathophysiology, timing to gestational biology, and delivery to human behavior.

As research continues—including an ongoing NIH-funded trial (NCT05238411) examining Cleodora’s impact on postpartum depression biomarkers—the foundational data already affirms its role in modern, responsive prenatal care. It is a tool that belongs in every perinatal provider’s toolkit—not as a last resort, but as a first-line strategy for iron repletion with integrity.